EARLY ACCESS AGREEMENTEarly Access Agreement • June 19th, 2015 • Celsion CORP • Pharmaceutical preparations
This exclusive Early Access Agreement (“Agreement”) is made and entered into the 13th day of January 2015 (“Effective Date”) by and between
AMENDMENT NO. 2 TO EARLY ACCESS AGREEMENTEarly Access Agreement • March 30th, 2018 • Hemispherx Biopharma Inc • Biological products, (no disgnostic substances)
This Amendment to the Early Access Agreement (the “Agreement”) dated 20th May 2016, by and between Hemispherx Biopharna, Inc. (“HEMISPHERX”), and Impatients N.V. (“IMPATIENTS”), who are each a “Party” and together the “Parties” to the Agreement, is entered into as of 28 of June 2017 (the “Amendment No. 2 Effective Date”).
EARLY ACCESS AGREEMENTEarly Access Agreement • August 12th, 2015 • Hemispherx Biopharma Inc • Biological products, (no disgnostic substances)
This exclusive Early Access Agreement (“Agreement”) is made and entered into the 3rd day of August, 2015, (“Effective Date”) by and between
EARLY ACCESS AGREEMENTEarly Access Agreement • February 6th, 2019
These terms (the “Early Access Agreement”) supplement the Anaplan SaaS Subscription Agreement, or other agreement governing Client’s use of the Anaplan hosted Service, (the “Client Agreement”) by and between Anaplan and your organization (as named in the Client Agreement). These terms, in addition to the Client Agreement, govern the use of the Early Access Technology, identified below, made available by Anaplan, and are effective immediately when you click accept or first access or use the Early Access Technology.
Early Access AgreementEarly Access Agreement • March 12th, 2021 • England and Wales
This agreement (hereinafter ‘Agreement’) define terms of early access to and use of the Minter Platform and Minter Network.
AMENDMENT NO. 1 TO EARLY ACCESS AGREEMENTEarly Access Agreement • March 30th, 2018 • Hemispherx Biopharma Inc • Biological products, (no disgnostic substances)
This First Amendment to the Early Access Agreement (the “Agreement”) dated 20th May 2016, by and between Hemispherx Biopharma, Inc. (“HEMISPHERX”), and Impatients N.V. (“IMPATIENTS”), who are each a “Party” and together the “Parties” to the Agreement, is entered into as of December 13, 2106 (the “Amendment No. 1 Effective Date”).
Addendum to the Early Access Agreement (as defined below)Early Access Agreement • November 16th, 2015 • Hemispherx Biopharma Inc • Biological products, (no disgnostic substances)
WHEREAS on August 3, 2015, IMPATIENTS N.V. (dba “myTomorrows”) a company formed and registered under the laws of the Netherlands, and located at Pilotenstraat 45, 1059 CH, Amsterdam, The Netherlands (hereinafter “myT”) and Hemispherx Biopharma, Inc. located at 1617 JFK Blvd, Philadelphia, PA 19103 (hereinafter “HEB”), each a “Party” and together the “Parties” entered into an early access agreement to make Ampligen available in a specific Territory under an Early Access Program (“EAP”), the “Early Access Agreement”, and
AMENDMENT NO. 3 TO EARLY ACCESS AGREEMENTEarly Access Agreement • March 30th, 2018 • Hemispherx Biopharma Inc • Biological products, (no disgnostic substances)
This third Amendment to the Early Access Agreement (the “Agreement”) dated 20th May 2016, by and between Hemispherx Biopharma, Inc. (“HEMISPHERX”), and Impatients N.V. (“IMPATIENTS”), who are each a “Party” and together the “Parties” to the Agreement, is entered into as of 14 February 2018 (the “Amendment No. 3 Effective Date”).
EARLY ACCESS AGREEMENTEarly Access Agreement • February 14th, 2014 • DanDrit Biotech USA, Inc. • Blank checks
This exclusive Early Access Agreement (“Agreement”) is made and entered into the 20th day of December 2013 (“Effective Date”) by and between
EARLY ACCESS AGREEMENT FOR SURVEY PURPOSESEarly Access Agreement • October 18th, 2018
AMENDMENT NO. 4 TO EARLY ACCESS AGREEMENTEarly Access Agreement • March 30th, 2018 • Hemispherx Biopharma Inc • Biological products, (no disgnostic substances)
This fourth Amendment to the Early Access Agreement (the “Agreement”) dated 20th May 2016, by and between Hemispherx Biopharma, Inc. (“HEMISPHERX”), and Impatients N.V. (“IMPATIENTS”), who are each a “Party” and together the “Parties” to the Agreement, is entered into as of 26 March 2018 (the “Amendment No. 4 Effective Date”).
EARLY ACCESS AGREEMENTEarly Access Agreement • July 27th, 2015
Sellers, and Purchasers, concerning property legally described as set forth in the below referenced Purchase and Sale agreement and commonly known as:
EARLY ACCESS AGREEMENTEarly Access Agreement • November 16th, 2015 • Hemispherx Biopharma Inc • Biological products, (no disgnostic substances)
This exclusive Early Access Agreement (“Agreement”) is made and entered into the 3rd day of August, 2015, (“Effective Date”) by and between
